SAB Biotherapeutics swings to Q3 net loss of $22.3 million
SABS•SAB Biotherapeutics reported a Q3 2026 net loss of $22.3 million, compared with net income of $45.4 million a year earlier. Cash, cash equivalents and investment securities totaled $205.3 million at September 30, with operational runway through 2028.
1. Quarterly results
SAB Biotherapeutics swung to a Q3 2026 net loss of $22.3 million from net income of $45.4 million a year earlier. Research and development expenses more than doubled to $18.1 million, while general and administrative expenses more than doubled to $7.8 million.
2. Cash and development
Cash, cash equivalents and investment securities totaled $205.3 million at September 30, providing operational runway through 2028. SAFEGUARD enrollment remains on track for completion in Q4 2026, with topline data expected in the second half of 2027. SAB-142 received FDA Fast Track designation in October 2026 for treatment of new-onset Stage 3 type 1 diabetes.
